Newsletter headings of "Mercury"

№ 1, 2023
Author:

THE REPUBLICAN UNITARY ENTERPRISE "BELMEDPREPARATY" IS THE FOUNDER OF THE PHARMACEUTICAL INDUSTRY IN BELARUS. SINCE 1929, IT HAS BEEN PRODUCING EFFECTIVE MEDICINES FOR THE PREVENTION AND TREATMENT OF A WIDE RANGE OF DISEASES.

97_11_03.jpg

Today "Belmedpreparaty" RUE is an export-oriented enterprise and a leading manufacturer of medicines in the Republic of Belarus. Keeping to its main mission, the company produces a wide range of affordable and high-quality medicines and ensures people's health and life.

"Belmedpreparaty" RUE has registered and locally produces about 350 kinds of medicines and 36 API's (active pharmaceutical ingredients). The medicines are designed for oral, parenteral and topical use and are manufactured in the following forms: solutions for infusions and injections, lyophilized and sterile packaged powders for injections and infusions, coated and uncoated tablets; solid gelatin capsules; powders and granules for oral solutions and suspensions; tinctures; eye and nasal drops; ointments, creams, gels.

Moreover, as part of the measures to prevent the spread of coronavirus and the disease caused by SARS-CoV-2, "Belmedpreparaty" RUE has carried out the project for the full-cycle production of Gam-COVID-Vac and Sputnik Light vaccines. The production of these medicines has been mastered through technology transfer in association with N.F.Gamaleya Federal Research Center for Epidemiology and Microbiology  (the Russian Federation).

Medicines of "Belmedpreparaty" are constantly in demand among business partners, practicing physicians, pharmacists and, of course, consumers.

97_11_01.jpg

The enterprise has two manufacturing sites in the Belarusian capital, Minsk, as well as production capacities in Skidel and Lida. Each site has its own engineering infrastructure, which fully satisfies the existing needs and has reserves for increasing outputs.

Over the past few years, "Belmedpreparaty" RUE has performed complete technical upgrade; new equipment from the world's leading vendors (Italy and Germany) has been installed.

For example, in 2014, a modern facility for the production of antitumor medicines was set up under the investment project "Reconstruction of the production of antitumor medicines in the form of lyophilized and sterilely ­packaged powders for injections". The main challenge of such a unique for Belarus and the CIS countries project was the insulator-design manufacture of cytostatic antitumor medicines. This allows performing technological processes in total isolation from the staff and work environment. Another advantage of this project is zero emission into the atmosphere.

Nowadays, more than 90 percent of products are manufactured at ­modern production capacities, certified ­according to the Good Manufacturing Practice (GMP) standards by the regulatory authorities of Belarus, Russia, Ukraine and Romania.

GMP is the international manufac­turing practice standard, that confirms the safety of products. Following this standard means a holistic approach to production and laboratory tests, full control of raw materials, intermediates and finished product throughout the shelf life.

According to the approved standards and procedures, the company's personnel carry out quality control of raw and packing materials, intermediate and finished products, inspect the stability of medicines, collect substances and finished products samples. "Belmedpreparaty" RUE hereby guarantees the quality of products at all manufacturing stages.

It is also worth noting that the enterprise has been accredited as a scientific organization and has Research and Development Department. The Department's experts create modern, demanded import-substituting medicines that are pharmaceutically and pharmacologically equivalent to the original ones. Dynamic innovation allows increasing the range by 10–15 new medicines annually.

Since its foundation, RUE "Belmed­preparaty" has received 102 patents for innovations, both national (patents of the Republic of Belarus, the Russian Federation, Ukraine) and regional ­Eurasian patents.

97_11_02.jpg

All the above benefits ensure that "Belmedpreparaty" RUE takes a leading position in the Belarusian pharmaceutical industry and steadily expands its share in foreign markets. The enterprise exports about 40 percent of products and has 585 foreign licenses. Today, products are exported to 30 countries of the world, including the CIS, European, African countries, as well as Vietnam, ­Syria, Afghanistan, Pakistan, Iraq. The main export market is the Russian Federation.

In 2021, the first batches of medicines were supplied to the UAE, Kenya and Lebanon, in 2022 – to Serbia. The company's future plans include further development of new and emerging markets in Southeast Asia, the Persian Gulf and Africa.

Year after year, "Belmedpreparaty" RUE expands its product line, develops new medicines and introduces them into production, increasing the enterprise's competitiveness in foreign markets and enhancing the share of exports.

The company's team is open to new partnerships and bases its business relations on the principles of mutually beneficial cooperation and respect.